December 6, 2022 7:57am

End of year trading: Take any profits if a gain hits at least 10%. If new buys go the wrong way, cut losses when the stock is 3% to 4% down, instead of waiting for the 7% rule to trigger

Indications:  5 Positive Indication and 1 Negative Indication

News: Sage Therapeutics (SAGE +$0.13) and Biogen (BIIB +$1.50) complete rolling submission of New Drug Application (NDA) for Zuranolone in the treatment of major depressive disorder and postpartum depression. Zuranolone is being evaluated as a short course, rapid-acting, oral medication for major depressive disorder (MDD) and postpartum depression (PPD).

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.07% or (+22 points), S&P futures are UP +0.09% or (+3 point) and NASDAQ futures are UP +0.19% or (+22 points) early in the pre-open – so far,

Stock futures are struggling the upside on Tuesday,

European markets were slightly lower,

Asia-Pacific markets were mixed

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes fell Monday on fears that the Fed may continue tightening until it tips the economy into a recession.

  • The Dow closed DOWN -482.78 points (-1.40%), the S&P close DOWN -72.86 points (-1.79%) while the Nasdaq closed DOWN -221.56 points (-1.93%)

Economic Data Docket: international trade for insight into the strength of the U.S. and global economy.

 

Monday’s (12/5) … RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: down shifting on a treacherous path. The Cell and gene therapy sector gives-up any gains.” … https://www.regmedinvestors.com/articles/12730

 

Ebb and flow:

Q4 – December – 2 negative and 1 positive close

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive indication:

Solid BioSciences (SLDB) closed down -$0.31 to $6.46b after Friday’s +$0.12 with a positive +$0.26 or +4.02% pre-open indication,

Beam Therapeutics (BEAM) closed down -$2.45 to $44.37 after Friday’s +$0.99, Thursday’s -$0.36, Wednesday’s +$2.58, Tuesday’s +$0.43 and last Monday’s -$1.10 with a positive +$0.63 or +1.42% pre-open indication.

BioLife Solutions (BLFS) closed down-$3.03 to $18.90 with a positive +$0.89 to +4.71% pre-open indication.

CRISPR Therapeutics (CRS)closed down -$0.45 to $54.34 with a positive +$0.29 or +0.56% pre-open indication.

Sage Therapeutics (SAGE) closed down -$0.09 to $43.52 with a positive +$0.13 or +0.30% pre-open indication.

 

Negative Indication:

Ultragenyx (RARE) closed down -$0.34 to $39.83 after Friday’s +$2.36 with a negative -$1.20 or -3.01% pre-open indication.

 

The BOTTOM LINE: I try to keep it simple and short!

Indecision of any moves in this sector is wrapped with pessimism as any sector move had a less than impressive week to date.

While it's certainly true that the Nasdaq is still in a confirmed uptrend, the crop of actionable stocks has been disappointing. It hasn't been easy increasing exposure.

In the very short term until December 31, investors may want to be cautious about making new buys. The market and sector face a big technical test with inflation and jobs reports likely to play a key role in how that plays out.

I’d be calculating selling for tax purposes.

Reiterating, “While it's fine putting money to work in the current stock market, keep your exposure on the conservative side with small positions to start. Just because the stock market is in a confirmed uptrend doesn't mean you have to be 100% invested. And don't be afraid to take a 10% gain if you have it, given the choppy nature of the market.” <IBD>

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

Reiterating, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.